List of Excipients in API ERLOTINIB HYDROCHLORIDE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ERLOTINIB HYDROCHLORIDE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | CELLULOSE, MICROCRYSTALLINE | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | FD&C YELLOW NO. 6 | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | HYDROXYPROPYL CELLULOSE | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | HYPROMELLOSES | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | LACTOSE MONOHYDRATE | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | MAGNESIUM STEARATE | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | SODIUM LAURYL SULFATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing ERLOTINIB HYDROCHLORIDE
Detailed excipient profiles for ERLOTINIB HYDROCHLORIDE
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ERLOTINIB HYDROCHLORIDE drug variants containing CELLULOSE, MICROCRYSTALLINE
ERLOTINIB HYDROCHLORIDE drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
ERLOTINIB HYDROCHLORIDE drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Physicians Total Care Inc | erlotinib hydrochloride | 54868-5290 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing FD&C YELLOW NO. 6
Excipient focus: HYDROXYPROPYL CELLULOSE
ERLOTINIB HYDROCHLORIDE drug variants containing HYDROXYPROPYL CELLULOSE
ERLOTINIB HYDROCHLORIDE drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| Mylan Institutional Inc | erlotinib hydrochloride | 42292-051 |
| Breckenridge Pharmaceutical Inc | erlotinib hydrochloride | 51991-890 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
ERLOTINIB HYDROCHLORIDE drug variants containing HYPROMELLOSE
ERLOTINIB HYDROCHLORIDE drug variants not containing HYPROMELLOSE
Excipient focus: HYPROMELLOSE 2910
ERLOTINIB HYDROCHLORIDE drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| Mylan Institutional Inc | erlotinib hydrochloride | 42292-051 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing HYPROMELLOSE 2910
Excipient focus: HYPROMELLOSES
ERLOTINIB HYDROCHLORIDE drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Physicians Total Care Inc | erlotinib hydrochloride | 54868-5290 |
| MSN LABORATORIES PRIVATE LIMITED | erlotinib hydrochloride | 69539-090 |
| Novadoz Pharmaceuticals LLC | erlotinib hydrochloride | 72205-080 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing HYPROMELLOSES
Excipient focus: LACTOSE MONOHYDRATE
ERLOTINIB HYDROCHLORIDE drug variants containing LACTOSE MONOHYDRATE
ERLOTINIB HYDROCHLORIDE drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ERLOTINIB HYDROCHLORIDE drug variants containing MAGNESIUM STEARATE
ERLOTINIB HYDROCHLORIDE drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Breckenridge Pharmaceutical Inc | erlotinib hydrochloride | 51991-890 |
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
ERLOTINIB HYDROCHLORIDE drug variants containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing MICROCRYSTALLINE CELLULOSE 102
Excipient focus: POLYETHYLENE GLYCOL
ERLOTINIB HYDROCHLORIDE drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Armas Pharmaceuticals Inc | erlotinib hydrochloride | 72485-217 |
| Armas Pharmaceuticals Inc | erlotinib hydrochloride | 72485-218 |
| Armas Pharmaceuticals Inc | erlotinib hydrochloride | 72485-219 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing POLYETHYLENE GLYCOL
Excipient focus: POLYETHYLENE GLYCOL 400
ERLOTINIB HYDROCHLORIDE drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| Mylan Institutional Inc | erlotinib hydrochloride | 42292-051 |
| Alembic Pharmaceuticals Limited | erlotinib hydrochloride | 46708-565 |
| Alembic Pharmaceuticals Inc | erlotinib hydrochloride | 62332-565 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing POLYETHYLENE GLYCOL 400
Excipient focus: POLYETHYLENE GLYCOL 4000
ERLOTINIB HYDROCHLORIDE drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Breckenridge Pharmaceutical Inc | erlotinib hydrochloride | 51991-890 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing POLYETHYLENE GLYCOL 4000
Excipient focus: PROPYLENE GLYCOL
ERLOTINIB HYDROCHLORIDE drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| MSN LABORATORIES PRIVATE LIMITED | erlotinib hydrochloride | 69539-090 |
| Novadoz Pharmaceuticals LLC | erlotinib hydrochloride | 72205-080 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing PROPYLENE GLYCOL
Excipient focus: SODIUM LAURYL SULFATE
ERLOTINIB HYDROCHLORIDE drug variants containing SODIUM LAURYL SULFATE
ERLOTINIB HYDROCHLORIDE drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
ERLOTINIB HYDROCHLORIDE drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
ERLOTINIB HYDROCHLORIDE drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
ERLOTINIB HYDROCHLORIDE drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Breckenridge Pharmaceutical Inc | erlotinib hydrochloride | 51991-890 |
| >Company | >Ingredient | >NDC |
ERLOTINIB HYDROCHLORIDE drug variants not containing SODIUM STEARYL FUMARATE
Excipient focus: TITANIUM DIOXIDE
ERLOTINIB HYDROCHLORIDE drug variants containing TITANIUM DIOXIDE
ERLOTINIB HYDROCHLORIDE drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
